Selected article for: "administration mechanical ventilation and median age"
Author: Chamorro-de-Vega, Esther; Rodriguez-Gonzalez, Carmen-Guadalupe; Manrique-Rodríguez, Silvia; Lobato-Matilla, Elena; García-Moreno, Felix; Olmedo, Maria; Correa-Rocha, Rafael; Valerio, Maricela; Aldámiz-Echevarria, Teresa; Machado, Marina; Sancho-Gonzalez, Milagros; Lopez-Bernaldo-de-Quirós, Juan Carlos; Ruiz-Briones, Paula; Romero-Jiménez, Rosa; Sarobe-González, Camino; Gimenez-Manzorro, Alvaro; Collado-Borrell, Roberto; Fernandez-Llamazares, Cecilia M; Revuelta-Herrero, Jose Luis; Somoza-Fernandez, Beatriz; Garcia-Sanchez, Sebastian; Taladriz-Sender, Irene; Bouza, Emilio; Herranz, Ana; Muñoz, Patricia; Sanjurjo, Maria
Title: Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain
  • Cord-id: pk2zscab
  • Document date: 2021_1_26
    • ID: pk2zscab
    Snippet: Background: We report the long-term outcomes, changes in laboratory parameters, the incidence of secondary nosocomial infections and treatment cost of a Spanish cohort of patients with severe COVID-19 that received tocilizumab (TCZ). Methods: Retrospective cohort of PCR confirmed adult patients who received TCZ from March 1 to 24, 2020 in a tertiary hospital was analyzed. Patients were followed up until 10 May 2020. Results: We included 162 patients (median age 64 years; 70.4% male). At time of
    Document: Background: We report the long-term outcomes, changes in laboratory parameters, the incidence of secondary nosocomial infections and treatment cost of a Spanish cohort of patients with severe COVID-19 that received tocilizumab (TCZ). Methods: Retrospective cohort of PCR confirmed adult patients who received TCZ from March 1 to 24, 2020 in a tertiary hospital was analyzed. Patients were followed up until 10 May 2020. Results: We included 162 patients (median age 64 years; 70.4% male). At time of TCZ administration, 48.1% of patients were on invasive mechanical ventilation (IMV). Over a median follow-up of 53 days, 46.9% of patients were discharge in good conditions and 19.8% were still hospitalized. The overall mortality was 33.3%, being higher in patients on IMV than those who did not (46.2% vs 26.7%, P < 0.001). A significant improvement in the lymphocyte count, C-reactive protein, lactate dehydrogenase, and D-dimer was observed. Overall, 43.2% patients presented nosocomial infections, causing death in 8%. Infections were more prevalent in ICU units (63.0% vs 17.1%, P < 0.001). The total cost of TCZ was €371,784. Conclusions: Among the patients who used TCZ, one third died, regardless the improvement in some inflammatory biomarkers. The incidence of secondary nosocomial infections was high.

    Search related documents:
    Co phrase search for related documents
    • abnormal finding and long period: 1
    • abnormal finding and lopinavir ritonavir: 1
    • access program and acute respiratory failure: 1
    • access program and long term outcome: 1
    • access program and low mortality: 1, 2
    • acute respiratory failure and admission respiratory status: 1
    • acute respiratory failure and live discharge: 1, 2
    • acute respiratory failure and liver renal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory failure and long cohort: 1, 2
    • acute respiratory failure and long period: 1
    • acute respiratory failure and long term outcome: 1, 2, 3, 4, 5
    • acute respiratory failure and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory failure and low intermediate: 1, 2, 3, 4
    • acute respiratory failure and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory failure and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory failure and low molecular weight heparin lmwh: 1, 2, 3, 4
    • acute respiratory failure and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • adequate indication and low mortality: 1
    • admission respiratory status and lopinavir ritonavir: 1